$135M series C buys Vividion flexibility to explore broad pipeline 

After its $135 million series C raise Wednesday, Vividion has everything in place to take advantage of the surging market for IPOs: a broad syndicate of crossover investors, pharma partners in BMS and Roche, a CEO in Jeff Hatfield who has already guided a company to NASDAQ, and seven cancer and immunology programs with preclinical proof of principle in hand. 

But Hatfield demurred when asked by BioCentury about Vividion’s trajectory to the public markets, and said the company’s deep-pocketed investors afford the company the flexibility to explore a platform that has to date generated more than 10,000 small molecules that drug different binding pockets than other companies “know about or go after.”...